Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Forte Biosciences, Inc.NASDAQ: FBRX
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets falls 46.1% from a year ago
Other current assets stood at $242K at the end of Q1 FY2026, down 46.1% from a year earlier and down 42.7% from the prior quarter. Over 3 fiscal years it compounded at +82.0% a year.
Context
- Other current assets amounted to 0.4% of total assets at the end of Q1 FY2026, down 0.6 pp from a year earlier.
- Other current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps falling in the next quarterly balance sheet after a -46.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 422K USD
- Year-over-year change
- +25.6%
- 4-year CAGR
- +47.6%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 422K | +25.6% |
| FY2024 | 2024-12-31 | 336K | +103.6% |
| FY2023 | 2023-12-31 | 165K | +135.7% |
| FY2022 | 2022-12-31 | 70K | -21.3% |
| FY2021 | 2021-12-31 | 89K | — |
Other Current Assets vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so other current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -46.1% is the 7th highest of 10, against a peer median of -29.2%.
- Other current assets amounts to 0.4% of total assets for FBRX, versus a peer median of 1.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $8.57M USD | -29.2% | — | 3.6% | |
| Mar 2026 | $4M USD | -25.7% | -46.8% | 1.4% | |
| Mar 2026 | $3.76M USD | +3.1% | -36.7% | 1.0% | |
| Mar 2026 | $2.08M USD | -54.4% | +98.9% | 1.4% | |
| Mar 2026 | $1.97M USD | -39.7% | -16.3% | 1.3% | |
| Mar 2026 | CHF 1.84M CHF | -11.0% | — | 2.1% | |
| Mar 2026 | $1.1M USD | -54.7% | -32.1% | 2.2% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $385.44K USD | +7.3% | +143.0% | 4.3% |
| Mar 2026 | $242K USD | -46.1% | +82.0% | 0.4% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $162K USD | -79.7% | +26.6% | 0.7% |
| Peer median (excluding FBRX) | — | -29.2% | -16.3% | 1.4% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.